Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women

Several clinical trials have demonstrated that antiretroviral (ARV) drugs, taken as pre-exposure prophylaxis (PrEP), can prevent HIV infection(1), with the magnitude of protection ranging from -49 to 86%(2–11). While these divergent outcomes are thought to be due primarily to product adherence(12),...

詳細記述

保存先:
書誌詳細
出版年:Nat Med
主要な著者: McKinnon, Lyle R., Liebenberg, Lenine J., Yende-Zuma, Nonhlanhla, Archary, Derseree, Ngcapu, Sinaye, Sivro, Aida, Nagelkerke, Nico, Lerma, Gerardo Garcia, Kashuba, Angela D., Masson, Lindi, Mansoor, Leila E., Karim, Quarraisha Abdool, Abdool Karim, Salim S., Passmore, Jo-Ann S.
フォーマット: Artigo
言語:Inglês
出版事項: 2018
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5893390/
https://ncbi.nlm.nih.gov/pubmed/29480895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.4506
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料